Insider · CIK 0001654058
Sean A. McCarthy
Files at CTMX (CytomX Therapeutics, Inc.). First filing Dec 22, 2023, latest Mar 19, 2026.
In brief
Sean A. McCarthy files SEC Form 4 as CEO and director at CTMX (CytomX Therapeutics, Inc.). Since Dec 22, 2023, Sean A. McCarthy has reported 0 open-market buys worth $0 and 6 open-market sells worth $1.5M, the latest filed on Mar 19, 2026.
A track record needs three past buys with six months of prices behind them; Sean A. McCarthy has 0, so none is measured yet.
The newest scored trade: sold $764k of CTMX on Mar 17, 2026, filed Mar 19, 2026, scored 42 (moderate), under a 10b5-1 plan. In the last 12 months: 0 buys worth $0 and 2 sells worth $1.2M.
Where the trades landed
Last year at the company this insider has traded most, with each buy and sell on the bar it happened.
CTMX: CytomX Therapeutics, Inc.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value. Click a marked bar to open the signal.Charts by TradingView Lightweight Charts™
Signals
This insider’s open-market buys and sells, scored.
| Score | Company | Value | Holdings | Price context | Filed |
|---|---|---|---|---|---|
| 42Moderate | CytomX Therapeutics, Inc. | $764k 118,969 shares | -10% | +1162% from low-19% from high | |
| 22Weak | CytomX Therapeutics, Inc. | $462k 101,793 shares | -9% | +870% from low-0% from high | |
| 36Weak | CytomX Therapeutics, Inc. | $149k 55,511 shares | -5% | +469% from low-18% from high | |
| 40Moderate | CytomX Therapeutics, Inc. | $23k 37,656 shares | -4% | - | |
| 46Moderate | CytomX Therapeutics, Inc. | $42k 20,223 shares | -4% | +104% from low-20% from high | |
| 40Moderate | CytomX Therapeutics, Inc. | $19k 13,551 shares | -3% | +25% from low-53% from high |
Planned sales
Form 144 notices this insider filed before selling restricted or control stock, newest first.
| Filed | Company | Shares | Value | Sale date | Past 3 months |
|---|---|---|---|---|---|
| Nov 6, 2025 | CTMX CytomX Therapeutics Inc. | 101,793 0.06% of outstanding | $462k | Nov 6, 2025 | none |
Transactions
Every row this insider has filed, 23 in all, newest first.
| Date | Company | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Mar 17, 2026 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock10b5-1 | -118,969 | $6.42 | $764k | 1,078,922 | Mar 19, 2026 |
| Feb 2, 2026 | CTMX CytomX Therapeutics, Inc. | AGrant or award Common Stock | +210,000 | $0.00 | $0 | 1,197,891 | Feb 4, 2026 |
| Feb 2, 2026 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +980,000 | $0.00 | $0 | 980,000 | Feb 4, 2026 |
| Nov 6, 2025 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Class A Common Stock10b5-1 | -101,793 | $4.54 | $462k | 987,891 | Nov 10, 2025 |
| Sep 26, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +570,000 | $0.00 | $0 | 570,000 | Sep 30, 2025 |
| Sep 26, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Performance Stock Units (PSUs)derivative | +285,000 | $0.00 | $0 | 285,000 | Sep 30, 2025 |
| Jun 13, 2025 | CTMX CytomX Therapeutics, Inc. | MOption exercise Common Stock | +150,000 | $0.00 | $0 | 1,145,195 | Jun 17, 2025 |
| Jun 16, 2025 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -55,511 | $2.69 | $149k | 1,089,684 | Jun 17, 2025 |
| Jun 13, 2025 | CTMX CytomX Therapeutics, Inc. | MOption exercise Performance Stock Unitsderivative | -150,000 | $0.00 | $0 | 0 | Jun 17, 2025 |
| Mar 18, 2025 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -37,656 | $0.60 | $23k | 995,195 | Mar 20, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Common Stock | +180,000 | $0.00 | $0 | 837,851 | Feb 6, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Common Stock | +195,000 | $0.00 | $0 | 1,032,851 | Feb 6, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +800,000 | $0.00 | $0 | 800,000 | Feb 6, 2025 |
| Feb 4, 2025 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +390,000 | $0.00 | $0 | 390,000 | Feb 6, 2025 |
| Mar 26, 2024 | CTMX CytomX Therapeutics, Inc. | MOption exercise Common Stock | +109,768 | $1.57 | $173k | 634,249 | Mar 28, 2024 |
| Mar 26, 2024 | CTMX CytomX Therapeutics, Inc. | MOption exercise Stock Option (Right to Buy)derivative | -109,768 | $0.00 | $0 | 0 | Mar 28, 2024 |
| Mar 19, 2024 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -20,223 | $2.09 | $42k | 524,481 | Mar 21, 2024 |
| Jan 18, 2024 | CTMX CytomX Therapeutics, Inc. | AGrant or award Common Stock | +90,000 | $0.00 | $0 | 544,704 | Jan 19, 2024 |
| Jan 18, 2024 | CTMX CytomX Therapeutics, Inc. | AGrant or award Stock Option (Right to Buy)derivative | +420,000 | $0.00 | $0 | 420,000 | Jan 19, 2024 |
| Jan 18, 2024 | CTMX CytomX Therapeutics, Inc. | AGrant or award Performance Stock Units (PSUs)derivative | +260,000 | $0.00 | $0 | 260,000 | Jan 19, 2024 |
| Dec 20, 2023 | CTMX CytomX Therapeutics, Inc. | SOpen-market sale Common Stock | -13,551 | $1.38 | $19k | 454,704 | Dec 22, 2023 |
| Dec 17, 2023 | CTMX CytomX Therapeutics, Inc. | MOption exercise Common Stock | +37,500 | $0.00 | $0 | 468,255 | Dec 19, 2023 |
| Dec 17, 2023 | CTMX CytomX Therapeutics, Inc. | MOption exercise Performance Stock Units (PSUs)derivative | -37,500 | $0.00 | $0 | 37,500 | Dec 19, 2023 |
Questions about Sean A. McCarthy
Answered from the filings on this page, as of the latest one.
Is Sean A. McCarthy buying or selling?
In the last 12 months Sean A. McCarthy reported 0 open-market buys worth $0 and 2 open-market sells worth $1.2M on SEC Form 4; the latest was sold $764k of CTMX on Mar 17, 2026. Grants, option exercises and tax withholding are not counted.
How did Sean A. McCarthy's past buys perform?
Not measured yet. InsiderTell needs three past buys with six months of prices to publish a track record, and Sean A. McCarthy has 0.
Where does Sean A. McCarthy file Form 4?
Sean A. McCarthy has filed Form 4 at CTMX (CytomX Therapeutics, Inc.) as CEO. A Form 4 is required of officers, directors and holders of more than 10% of a share class within two business days of a trade.
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.